Literature DB >> 23359763

Combined detection of serum matrix metalloproteinase 9, acetyl heparinase and cathepsin L in diagnosis of ovarian cancer.

Wei Zhang1, Xiao-Xia Hu, Xing-Zhi Yang, Qi Wang, Hong Cheng, Shu-Mei Wang, Yan-Ling Hu, Zhi-Jun Yang, Li Li.   

Abstract

OBJECTIVE: To investigate the clinic values of combining test of serum matrix metalloproteinase 9 (MMP-9), acetyl heparinase (Hpa) and Cathepsin L (CL) in diagnosis of ovarian cancer.
METHODS: Serum levels of MMP-9, Hpa and CL were detected in a total of 418 cases, including 217 cases with ovarian malignant tumor, 100 cases with ovarian benign tumor and 101 healthy controls, by using enzyme-linked immunosorbent assay (ELISA). Their correlation with clinicopathologic feature of ovarian malignant tumor was analyzed and their diagnosis performance was evaluated by receiver operating characteristic (ROC). The combined diagnosis model was established by logistic regression analysis.
RESULTS: The serum levels of MMP-9, Hpa and CL were significantly higher in patients with ovarian malignant tumor than in benign tumor and healthy control, the serum levels of CL and Hpa were higher in epithelial cancer than in non-epithelial tumor, and MMP-9, Hpa and CL were elevated in low grade and advanced stage compared to high grade and early stage. The sensitivity for diagnosis of ovarian malignant tumor from high to low was CL, Hpa and MMP-9, and the specificity was MMP-9, CL and Hpa. The united diagnosis model was established and showed the sensitivity and specificity of combined detection were 84.6% and 82.1%, respectively, which were significantly higher than a single tumor marker.
CONCLUSION: Serum MMP-9, Hpa and CL were correlated with ovarian malignant tumor and the combined detection of which may be valuable for clinical diagnosis of ovarian malignant tumor.

Entities:  

Keywords:  Acetyl heparinase; Cathepsin; Diagnosis; Matrix metalloproteinase 9; Ovarian cancer

Year:  2012        PMID: 23359763      PMCID: PMC3555258          DOI: 10.1007/s11670-012-0067-1

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  17 in total

1.  Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.

Authors:  Brian Nolen; Liudmila Velikokhatnaya; Adele Marrangoni; Koen De Geest; Aleksey Lomakin; Robert C Bast; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2010-03-24       Impact factor: 5.482

2.  Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial.

Authors:  Peeter Karihtala; Johanna Mäenpää; Taina Turpeenniemi-Hujanen; Ulla Puistola
Journal:  Anticancer Res       Date:  2010-03       Impact factor: 2.480

Review 3.  The heparanase system and tumor metastasis: is heparanase the seed and soil?

Authors:  Gil Arvatz; Itay Shafat; Flonia Levy-Adam; Neta Ilan; Israel Vlodavsky
Journal:  Cancer Metastasis Rev       Date:  2011-06       Impact factor: 9.264

4.  Heparanase-2 expression in normal ovarian epithelium and in benign and malignant ovarian tumors.

Authors:  Joel Pereira de Moura; Sérgio Mancini Nicolau; João Norberto Stávale; Maria Aparecida da Silva Pinhal; Leandro Luongo de Matos; Edmund Chada Baracat; Geraldo Rodrigues de Lima
Journal:  Int J Gynecol Cancer       Date:  2009-12       Impact factor: 3.437

5.  Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.

Authors:  L Manenti; P Paganoni; I Floriani; F Landoni; V Torri; A Buda; G Taraboletti; R Labianca; D Belotti; R Giavazzi
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

6.  Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer.

Authors:  Simon Fredriksson; Joe Horecka; Odd Terje Brustugun; Joerg Schlingemann; Albert C Koong; Rob Tibshirani; Ronald W Davis
Journal:  Clin Chem       Date:  2008-01-02       Impact factor: 8.327

7.  Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.

Authors:  Zoya Yurkovetsky; Shlomo Ta'asan; Steve Skates; Alex Rand; Aleksey Lomakin; Faina Linkov; Adele Marrangoni; Lyudmila Velikokhatnaya; Matthew Winans; Elieser Gorelik; G Larry Maxwell; Karen Lu; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2007-07-19       Impact factor: 5.482

8.  Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study.

Authors:  Paola Matarrese; Barbara Ascione; Laura Ciarlo; Rosa Vona; Carlo Leonetti; Marco Scarsella; Anna M Mileo; Caterina Catricalà; Marco G Paggi; Walter Malorni
Journal:  Mol Cancer       Date:  2010-08-04       Impact factor: 27.401

9.  Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors.

Authors:  Eva Kolwijck; Leon F A G Massuger; Chris M G Thomas; Paul N Span; Marta Krasovec; Janko Kos; Fred C G J Sweep
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-14       Impact factor: 4.553

10.  Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma.

Authors:  Shirley Ralph; Paul E C Brenchley; Angela Summers; Daniela D Rosa; Ric Swindell; Gordon C Jayson
Journal:  Cancer Sci       Date:  2007-04-05       Impact factor: 6.716

View more
  1 in total

1.  Impact of Human Cytomegalovirus Infection and its Immune Response on Survival of Patients with Ovarian Cancer.

Authors:  Angelique Flöter Rådestad; Atosa Estekizadeh; Huanhuan L Cui; Ourania N Kostopoulou; Belghis Davoudi; Angelica Lindén Hirschberg; Joseph Carlson; Afsar Rahbar; Cecilia Söderberg-Naucler
Journal:  Transl Oncol       Date:  2018-08-30       Impact factor: 4.243

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.